Unknown

Dataset Information

0

MRl of prostate cancer antigen expression for diagnosis and immunotherapy.


ABSTRACT:

Background

Tumor antigen (TA)-targeted monoclonal antibody (mAb) immunotherapy can be effective for the treatment of a broad range of cancer etiologies; however, these approaches have demonstrated variable clinical efficacy for the treatment of patients with prostate cancer (PCa). An obstacle currently impeding translational progress has been the inability to quantify the mAb dose that reaches the tumor site and binds to the targeted TAs. The coupling of mAb to nanoparticle-based magnetic resonance imaging (MRI) probes should permit in vivo measurement of patient-specific biodistributions; these measurements could facilitate future development of novel dosimetry paradigms wherein mAb dose is titrated to optimize outcomes for individual patients.

Methods

The prostate stem cell antigen (PSCA) is broadly expressed on the surface of prostate cancer (PCa) cells. Anti-human PSCA monoclonal antibodies (mAb 7F5) were bound to Au/Fe(3)O(4) (GoldMag) nanoparticles (mAb 7F5@GoldMag) to serve as PSCA-specific theragnostic MRI probe permitting visualization of mAb biodistribution in vivo. First, the antibody immobilization efficiency of the GoldMag particles and the efficacy for PSCA-specific binding was assessed. Next, PC-3 (prostate cancer with PSCA over-expression) and SMMC-7721 (hepatoma cells without PSCA expression) tumor-bearing mice were injected with mAb 7F5@GoldMag for MRI. MRI probe biodistributions were assessed at increasing time intervals post-infusion; therapy response was evaluated with serial tumor volume measurements.

Results

Targeted binding of the mAb 7F5@GoldMag probes to PC-3 cells was verified using optical images and MRI; selective binding was not observed for SMMC-7721 tumors. The immunotherapeutic efficacy of the mAb 7F5@GoldMag in PC-3 tumor-bearing mice was verified with significant inhibition of tumor growth compared to untreated control animals.

Conclusion

Our promising results suggest the feasibility of using mAb 7F5@GoldMag probes as a novel paradigm for the detection and immunotherapeutic treatment of PCa. We optimistically anticipate that the approaches have the potential to be translated into the clinical settings.

SUBMITTER: Ren J 

PROVIDER: S-EPMC3384648 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

MRl of prostate cancer antigen expression for diagnosis and immunotherapy.

Ren Jing J   Wang Fang F   Wei Guangquan G   Yang Yong Y   Liu Ying Y   Wei Mengqi M   Huan Yi Y   Larson Andrew C AC   Zhang Zhuoli Z  

PloS one 20120627 6


<h4>Background</h4>Tumor antigen (TA)-targeted monoclonal antibody (mAb) immunotherapy can be effective for the treatment of a broad range of cancer etiologies; however, these approaches have demonstrated variable clinical efficacy for the treatment of patients with prostate cancer (PCa). An obstacle currently impeding translational progress has been the inability to quantify the mAb dose that reaches the tumor site and binds to the targeted TAs. The coupling of mAb to nanoparticle-based magneti  ...[more]

Similar Datasets

| S-EPMC6308151 | biostudies-literature
| S-EPMC3263933 | biostudies-literature
| S-EPMC7941450 | biostudies-literature
| S-EPMC7013283 | biostudies-literature
| S-EPMC7269990 | biostudies-literature
| S-EPMC7409298 | biostudies-literature
| S-EPMC4928360 | biostudies-literature
| S-EPMC8899981 | biostudies-literature
| S-EPMC6144584 | biostudies-literature